Khaldoun Kerrou

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

José Manuel Pérez-García, Géraldine Gebhart, Manuel Ruíz Borrego et al. · The Lancet Oncology · 2021 · 152 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +5

PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT

Jean‐Noël Talbot, Fabrice Gutman, Jean‐Didier Grangé et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2006 · 131 citations

Positron Emission Tomography, Hepatology, Medical Imaging +12

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego et al. · The Lancet · 2024 · 69 citations

Breast Oncology, Medicine, Chemotherapy De-escalation +4

Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma

Laëtitia Vercellino, Françoise Montravers, Vincent de Parades et al. · International Journal of Colorectal Disease · 2010 · 58 citations

Positron Emission Tomography, Health Sciences, Oncologic Imaging +7

Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera.

Françoise Montravers, Dany Grahek, Khaldoun Kerrou et al. · PubMed · 2000 · 52 citations